IDT Australia Restricted (ASX: IDT) is pleased to announce that the Division of Health  ‐ Office of Drug Handle has granted the Corporation a Medicinal Cannabis Manufacturing Licence below the Narcotic Drugs Act 1967.

The Licence authorises IDT to undertake the following activities in specified regions of the Company’s licenced premises:

a) the manufacture of extracts and tinctures of cannabis and cannabis resin (Drug) in accordance with 1 or far more manufacture permits

b) activities relating to such manufacture, which includes but not restricted to the following (as applicable):

i. the provide of the Drug

ii. the packaging, transport, storage, possession and handle of the Drug

iii. disposal or destruction of the Drug.

 IDT’s manufacturing and packaging facilities currently have in location a Superior Manufacturing Practices (GMP) licence issued by the Therapeutic Goods Administration (TGA).  The facilities also have the requisite Poisons Licensure for handling specific Schedule eight and 9 drugs.

The Medicinal Cannabis Manufacturing Licence complements IDT’s current pharmaceutical manufacturing capabilities and facilities.    IDT’s lengthy history of manufacturing each Active Pharmaceutical Components (API’s) and Completed Dosage Types fits effectively with the possibilities presently accessible in the medicinal cannabis space.    IDT’s API manufacturing skills let the Corporation to GMP manufacture a variety of precursor goods such as cannabis resins and cannabinoids.  The Corporation is also in a position to create GMP completed dosage types such as tinctures, liquids and strong oral dose (tablets and capsules) for each clinical trial and industrial applications.

  “We are exceptionally pleased to have secured a Medicinal Cannabis Manufacturing Licence from the Workplace of Drug Control” stated IDT’s Chief Executive Officer Dr David Sparling.    “With IDT’s lengthy established facilities and knowledge in GMP pharmaceutical manufacturing, a licence in our personal appropriate to manufacture Medicinal Cannabis goods puts IDT in a incredibly powerful position in the fascinating and quickly expanding international medicinal cannabis industry.”

For additional details please get in touch with: IDT Australia Restricted Dr David Sparling – Chief Executive Officer   0417 721 972